key: cord-1050955-rbgkstvj authors: Zhao, Qing; Fang, Xiaokai; Pang, Zheng; Zhang, Bowen; Liu, Hong; Zhang, Furen title: COVID‐19 and cutaneous manifestations: A systematic review date: 2020-06-28 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.16778 sha: a8fbbe43492a6a5e617d17bf6ef28277dfb4406a doc_id: 1050955 cord_uid: rbgkstvj The cutaneous manifestations of COVID‐19 patients have been increasingly reported, but not summarized, and the potential mechanisms remain to be investigated. Herein, we performed a comprehensive review of literatures (from inception to May 30, 2020) using PubMed, CNKI, medRxiv, and bioRxiv with the terms “((novel coronavirus) OR (2019 novel coronavirus) OR (2019‐nCoV) OR (Coronavirus disease 2019) OR (COVID‐19) OR (SARS‐CoV‐2)) AND ((Dermatology) OR (skin) OR (rash) OR (cutaneous))” and “((ACE2) OR (Angiotensin‐converting enzyme)) AND ((skin) OR (epidermis) OR (dermis))”. Totally, 44 articles met the inclusion criteria. A total of 507 patients with cutaneous manifestations were summarized, and 96.25% patients were from Europe. The average age of the patients was 49.03 (range: 5‐91) with a female ratio of 60.44%. The skin lesions were polymorphic, and erythema, chilblain‐like and urticarial lesions were most common, occurring on an average of 9.92 days (range: 1‐30) after the onset of systemic symptoms. The receptor of SARS‐CoV‐2, ACE2, was found to be expressed on skin, mainly on keratinocytes. Our review systematically presented the clinical characteristics of 507 patients and showed that skin might be the potential target of the infection according to ACE2 expression. More work should be done to better understand the underlying pathogenesis. In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was firstly reported in Wuhan, China, as an etiological agent causing a new infectious respiratory disease (coronavirus disease 2019, COVID-19) 1. SARS-CoV-2 spread rapidly worldwide through human-to-human transmission and COVID-19 has been declared as a pandemic emergency by World Health Organization (WHO) on March, 2020. By May 30, 2020, 5,701 ,337 patients were confirmed as COVID-19 cases and 357,688 patients were dead. The main clinical manifestations of COVID-19 were fever, cough, fatigue, sputum production, dyspnea, and muscle aches2, 3. The diarrhea, olfactory and gustatory impairments caused by COVID-19 were also reported but less common4, 5 However, the researches on the pathogenesis of cutaneous manifestations of COVID- 19 have not been performed yet. Given that angiotensin-converting enzyme 2 (ACE2) is a crucial functional receptor of SARS-CoV-28-12. Exploration of the ACE2 expression in skin tissues could facilitate to clarify the mechanisms involved in cutaneous manifestations of COVID-19. Herein, to gain an in-depth understanding of the COVID-19, we summarized the publications related to the cutaneous manifestations of COVID-19 cases and the ACE2 expression in skin tissues. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched in the Medline database (PubMed), CNKI (https://www.cnki.net/), medRxiv (https://www.medrxiv.org/), and bioRxiv This article is protected by copyright. All rights reserved (SARS-CoV-2)) AND ((Dermatology) OR (skin) OR (rash) OR (cutaneous))" and "((ACE2) OR (Angiotensin-converting enzyme)) AND ((skin) OR (epidermis) OR (dermis))". Searches were limited to the publications before May 30, 2020. Case reports, clinical analysis and fundamental research discussing the cutaneous manifestations and expression of ACE2 in skin were included. Unavailable articles, review articles, expert consensus, medical hypothesis articles, and the articles focusing on the below aspects were excluded: the skin problems of medical staff caused by using protective equipment, the effects of the epidemic on the use of immunosuppressive agents and other drugs in dermatology, the effects of dermatological instruments, and the effects resulted from the treatment of COVID-19 transmission. The cases with clinical diagnosis of the disease (suspected cases) were included in addition to the cases confirmed of COVID-19 by viral nucleic acid detection, viral gene sequencing and serum antibody tests (Supplemental Fig.1 ). Data from 164 papers were collected. After screening, 120 of them were excluded. We recruited 44 articles, including 38 case reports (Supplemental table 1) and 6 publications of ACE2 expression in skin tissues (Supplemental table 2 ). Lu et al. 13 This article is protected by copyright. All rights reserved Among the 450 patients reported the basic information, the ratio of male to female was 178/272. The mean age of patients was 49.03 (range: 5-91). According to a previous study of COVID -19 in China, male patients accounted for about 53%, and the average age was 49.5450. Thus, we assumed that the incidence of skin lesions in COVID-19 patients was regardless of ages and genders. Eighty-eight of the 507 patients provided the information on the onset of skin manifestations. Among them, lesions occurred on average 9.92 days (range: 1-30) after the onset of systemic symptoms including fever, cough, dyspnea, diarrhea, and fatigue. In addition, the longest incubation of lesions was 30 days 17 , and it was noteworthy that 13 patients (14.77%) had skin lesions as the first symptom17, 25, 26, 29, 31, 45, 47, 49. All 507 patients had descriptions on their clinical manifestations. We found that the skin symptoms of COVID-19 patients were polymorphic. The most common skin lesion was erythema, which was observed in 224 patients (44.18%) and distributed on patients' trunk, extremities, flexural regions, face, and mucous membranes. Moreover, the erythema lesions were also confined to specific sites, such as the heels14 without other triggers such as exposure. Chilblain-like lesions The severity of pneumonia in COVID-19 patients presenting cutaneous manifestations varied. This article is protected by copyright. All rights reserved Zhang et al. 15 reported 7 COVID-19 patients with critical symptoms. All the patients had extremity ischemia with varied severity, which was manifested as cyanosis, purpura, hemophysallis and dry gangrene. In addition, the skin of two patients become darker than usual after treatment, which might be related to severe symptoms, multiple organ damage and drug treatment51. We speculate that the skin changes in these patients might be caused by multiple organ damages or systemic ischemia, suggesting a severe condition. For the remaining cases, Only 5 patients had clear information about the severity of COVID-19, including one mild, two ordinary, and two severe cases, according to the diagnostic criteria52. Fibrinogen and fibrin degradation product (FDP) were increased in 6 patients, and prothrombin time (PT) was prolonged in 4 patients15. Two patients showed thrombocytopenia, corresponding to a skin lesion that includes petechiae21. This article is protected by copyright. All rights reserved Ten patients had the complication of hypertension and 6 patients had diabetes. In a study by Galván et al. 18 , the number of smokers reached 44, accounting for 11.73% of a total of 375 cases. For the prognosis of all 507 patients, only 4 cured and 13 dead cases were clearly described. In the seven critical patients, five patients died and the two others were still under treatment after 26 days of follow-up, and the causes of death were circulatory failure resulted from severe hypoxemia and respiratory acidosis15. In addition, a 71-year-old male patient died due to his advanced age and multiple underlying diseases26. In a study by Galván et al. 18 , there were 369 survival and 6 dead cases. According to the description of the symptoms, we speculated that most of the patients had a relatively good prognosis and the reported death rate was 2.56% (13/507). For skin lesions, 39 patients resolved spontaneously or with some basic medication within a week, and other cases did not provide details data. It remains to be discussed whether 7 patients develop skin lesions after taking a drug that targets COVID-19. Although some drugs, such as paracetamol, hydroxychloroquine, and lopinavir/ritonavir, were commonly used with rare adverse reactions, it is still debatable whether the skin lesions were caused by viral infections or adverse drug reactions20, 33, 48, 53. All the information of the 507 COVID-19 patients were summarized in Table 1 . The results were further confirmed by IHC, which showed the ACE2-positive keratinocytes in the stratum basal, the stratum spinosum, and the stratum granulosum of epiderma. In addition, Li et al. found that CD8+ T cell enrichment had significant positive correlations with the ACE2 expression in the skin59. Infection with SARS-CoV-2 causes a broad spectrum of clinical syndromes, ranging from mild pneumonia to acute respiratory distress syndrome. Although cutaneous manifestations are rare, the number of COVID-19 patients with skin involvement has been reported to be increased. However, up to date, no in vitro or in vivo experiments have been performed to confirm whether SARS-Cov-2 could spread through skin. In this review, we found that ACE2 was expressed in the skin, especially in keratinocytes. This provides an evidence for percutaneous infection or the entry of virus into patients through skin tissue. Furthermore, SARS-CoV-2 RNA was detected in blood samples from 22% patients60. Thus, it is possible that the ACE2 expression in skin cells could be induced by viral infection via hematogenous dissemination, especially for the patients who were in a state of viraemia. More biopsy specimens should be collected to detect whether the presence of virus in skin lesions to confirm it. According to our review, erythematous rash is the most common feature among 507 patients. Chilblain-like lesions, ischemic lesions and ecchymotic acral lesions were also observed in COVID-19 patients. It has been reported that blood coagulation is altered in COVID-19 patients and the acro-ischemia might be associated with the hypercoagulation status in severe COVID-19 patients15. Recently, these types of skin lesions were also found in asymptomatic or mildly symptomatic patients, probably caused by a coagulation disorder or a hypersensitivity reaction17, 65 . Unfortunately, the mechanisms of cutaneous manifestations are only hypothetical at present. Interestingly, it is likely that the incidence of skin rashes among COVID- 19 This article is protected by copyright. All rights reserved unreported cases, or regional differences. It is noteworthy that skin rashes are also observed in general population. For example, in a population-based study, up to 1% of the general population in the USA and Europe suffered from chronic urticarial at some point in their lifetime68. The ratio was significantly higher in Asia, which was about 9-20%69. Urticaria-like lesions were presented in 16.37% COVID-19 patients with skin manifestation in our study. Therefore, we could not rule out that the cutaneous lesions of COVID-19 patients were merely an incidental phenomenon based on the population incidence. In conclusion, our review summarized the clinical characteristics of skin lesions in COVID-19 patients and the possible mechanisms by reviewing the ACE2 expression in skin tissues. However, we should acknowledge that lots of questions regarding COVID-19 remain unexplored. More clinical data should be collected, and more researches should be carried out for a better understanding of the cutaneous manifestations caused by COVID-19. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms Clinical Characteristics of Coronavirus Pneumonia 2019 (COVID-19): An Updated Systematic Review Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus Smell and taste dysfunction in patients with COVID-19 Reply to: Personal Protective Equipment Recommendations Based on COVID-19 Route of Transmission Cutaneous manifestations in COVID-19: a new contribution Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin SARS-CoV-2 entry factors are highly expressed in Accepted Article This article is protected by copyright. All rights reserved nasal epithelial cells together with innate immune genes SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients Cutaneous manifestations in COVID-19: a first perspective Vascular skin symptoms in COVID-19: a french observational study Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases A distinctive skin rash associated with Coronavirus Disease Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies COVID-19 can present with a rash and be mistaken for dengue Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome Chilblain-like lesions on feet and hands during the COVID-19 Pandemic Cutaneous Clinico-Pathological Findings in three COVID-19-Positive Patients Observed in the Metropolitan Area of SARS-CoV-2 infection presenting as a febrile rash Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection Cutaneous manifestation of COVID-19 in images: A case report Morbilliform Exanthem Associated with COVID-19. JAAD Case Rep 2020 A Case of COVID-19 Pneumonia in a Young Male with Full Body Rash as a Presenting Symptom Urticarial eruption in COVID-19 Accepted Article This article is protected by copyright. All rights reserved infection Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: A diagnostic clue? Reply to "COVID-19 can present with a rash and be mistaken for Dengue": Petechial rash in a patient with COVID-19 infection Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Cutaneous lesions in a patient with COVID-19: are they related? Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Oral vesiculobullous lesions associated with SARS-CoV-2 infection Histologic features of long lasting chilblain-like lesions in a pediatric COVID-19 patient Clinical and histological characterization of vesicular COVID-19 rashes: A prospective study in a tertiary care hospital Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings Accepted Article This article is protected by copyright. All rights reserved Chilblains-like lesions in children following suspected Covid-19 infection Urticarial eruption in Coronavirus Disease 2019 (COVID-19) infection: a case report in Tangerang, Indonesia Acute Generalized Exanthematous Pustulosis with Erythema Multiforme-Like lesions in a COVID-19 woman Cutaneous manifestations of COVID-19: Report of three cases and a review of literature Periorbital Erythema as a Presenting Sign of Covid-19 Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection": Urticaria-like lesions in COVID-19 patients are not really urticaria. A case with clinicopathologic correlation Late onset of acral necrosis after SARS-CoV-2 infection resolution A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect? Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19? Characteristics of and Important Lessons From the Coronavirus Disease Accepted Article This article is protected by copyright. All rights reserved 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention The skin of COVID-19 patients become black, do not ignore pharmacological causes Novel coronavirus: where we are and what we know A distinctive skin rash associated with Coronavirus Disease Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme Critical role of the endogenous renin-angiotensin system in maintaining self-renewal and regeneration potential of epidermal stem cells ACE and ACE2 expression in normal and malignant skin lesions Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis High expression of ACE2 on the keratinocytes reveals skin as a potential target for SARS-CoV-2 Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Accepted Article This article is protected by copyright. All rights reserved Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking Association between urticaria and virus infections: A systematic review COVID-19: immunopathology and its implications for therapy Chilblain -like lesions on feet and hands during the COVID-19 Pandemic Clinical Characteristics of Coronavirus Disease 2019 in China Cutaneous manifestations in COVID-19: a first perspective " by Recalcati S Chronic Urticaria: An Overview of Treatment and Recent Patents Introduction to "urticaria" special issue of dermatology bulletin This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved